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Open access una b s t r a c t
Gene ampliﬁcations and deletions are common changes in human cancer cells. Previous studies indicate
that the regions, where the ACHE (7q22) and BCHE (3q26.1-q26.2) genes are localized, are suffering such
structural modiﬁcations in breast cancer. Therefore, the products of these genes, acetylcholinesterase and
butyrylcholinesterase, respectively, are related to the process of cell differentiation and proliferation, as
well as apoptosis. This study also included two other genes involved in tumorigenesis, the EPHB4 (7q22.1)
and MME (3q21-27). The aim of this study was to verify ampliﬁcation and/or deletion in the ACHE, BCHE,
EPHB4 and MME genes in 32 samples of sporadic breast cancer. The gene alterations were detected using
real-time PCR and determined by relative quantiﬁcation with the standard curve method. All samples
presented genetic alterations, showing a higher tendency for ampliﬁcation of the ACHE (62.5% vs.
37.5%; p > 0.1) and EPHB4 (53.13% vs. 46.88%; p > 0.5) genes, and for deletions of the BCHE andMME genes
(56.25% vs. 43.75% for both; p > 0.5). A positive correlation was found between alterations in ACHE–EPHB4
and BCHE–MME pairs (rs = 0.5948; p = 0.0004; rs = 0.3581; p = 0.0478, respectively) indicating that these
changes comprise a wide region. In conclusion, the results suggest that these genomic regions may con-
tain important genes for this pathology, such as the oncogenes MET (7q31) and PIK3CA (3q26), and thus
being interesting targets for future studies in breast cancer research.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction lyzing choline esters, also have a non-cholinergic activity related toStructural genomic alterations such as gene ampliﬁcations and
deletions commonly contribute to development and progression of
tumors. During oncogenesis, these changes occur from successive
chromosomal aberrations that lead to gains or losses of parts of
the genome of the tumor cells, causing aberrant function of genes
that regulate negatively and positively the cell proliferation, apop-
tosis, genomic stability, angiogenesis, invasion and metastasis
[1,2]. The identiﬁcation of chromosome regions suffering such
alterations as well as the role of genes within these regions is
important in cancer research [3,4].
ACHE and BCHE genes chromosome regions (7q22 and 3q26.1-
q26.2, respectively) are frequently altered in different types of can-
cer, such as leukemia [5], lung [6], head and neck [7], lymphoma
[8] and breast [9]. In a previous study, ACHE and BCHE genes were
found altered (ampliﬁed or deleted) in most sporadic breast cancer
patients [10].
The products of these genes are, respectively, acetylcholinester-
ase (AChE) and butyrylcholinesterase (BChE) which, besides hydro-. Souza).
der the Elsevier OA license.cell growth. During neural system development, both AChE and
BChE participate in cell differentiation and proliferation [11]. By
regulating multipotent stem cell proliferation AChE has a role in
haematopoiesis, and also in apoptosis in cells undergoing erythroid
and myeloid differentiation [5]. Considering the non-cholinergic
activities of AChE and BChE there is evidence that both have a role
in tumorigenesis [12].
The aim of the present study was to investigate if the copy num-
ber variation found in sporadic breast cancer patients is restricted
to ACHE and BCHE genes or if it affects a larger chromosome region.
To accomplish that, we included in the study the EPHB4 (7q22.1)
and MME (3q21-27) genes, which products (receptor EphB4 and
neprylisin, respectively), are altered in prostate cancer [13], non-
Hodgkin’s lymphoma [14], endometrium/ovary cancer [15] and
breast cancer [16,17].2. Material and methods
2.1. Samples
This study used samples of breast carcinoma and peripheral
blood from 32 patients from Hospital Nossa Senhora das Graças
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were classiﬁed histopathologically according to World Health
Organization Classiﬁcation of Tumours. The most frequent histo-
logical type found was invasive ductal carcinoma (79.3%), followed
by lobular carcinoma (10.3%) and tubular carcinoma (3.5%). Inva-
sive papillary carcinoma and poorly differentiated carcinoma ac-
count together for 6.9% of histological types. The mean age of the
patients was 58 ± 16.5 years. The institutional Ethics Committee
approved the study. All experiments were conducted in accordance
with the Declaration of Helsinki.2.2. DNA Analysis
Total genomic DNA was extracted from peripheral blood sam-
ples by a salting-out method [18] and by phenol–chloroform from
tumor tissue [19]. Samples were diluted to 20 ng/ll ﬁnal concen-
tration of DNA.
Genomic alterations were identiﬁed using real-time PCR
(TaqMan probes). Each reaction was conducted as follows: 5 ll of
Master MIX QuantiFast Probe PCR; 2 ll of genomic DNA; 0.5 ll of
Prime Time qPCR Assay and 2.5 ll of ultrapure water. Besides the
four target genes (ACHE, BCHE, EPHB4 andMME), RNA 18S ribosomal
1 (18S), homologof Pumilio,Drosophila, 1 (PUM1) andb-actin (ACTB)
were used as endogenous control genes by having levels of ampliﬁ-
cation and expression in tumor tissues unchanged [20,21]. All the
reactions were performed in three replicates for quality control.
Relative quantities were obtained using the standard curve
method, which compares patient sample results with data ob-
tained from a standard curve (dilution factor 4). Standard dilution
series were as follows: 256; 64; 16; 4 and 1 ng/ll. MastercyclerTable 1
Relative amount (Q) of ACHE, EPHB4, BCHE andMME genes and Standard Deviation (S.D.) in
Case Histological type ACHE Q(mean) ± S.D.(mean) Alt EPHB4 Q(mean) ± S.D.(m
4 NI 1.14 ± 0.003 A 1.60 ± 0.003
5 DC 2.01 ± 0.020 A 1.87 ± 0.003
13 DC 1.43 ± 0.011 A 1.55 ± 0.011
22 DC 1.18 ± 0.018 A 1.41 ± 0.020
3 DC 0.68 ± 0.002 D 0.61 ± 0.002
14 DC 0.40 ± 0.004 D 0.88 ± 0.001
16 DC 0.69 ± 0.005 D 0.72 ± 0.001
18 DC 0.36 ± 0.003 D 0.40 ± 0.002
28 DC 0.35 ± 0.016 D 0.73 ± 0.015
6 DC 1.94 ± 0.019 A 1.44 ± 0.013
10 DC 3.03 ± 0.122 A 2.39 ± 0.061
12 DC/LC 1.61 ± 0.004 A 1.96 ± 0.005
25 DC 3.68 ± 0.030 A 3.41 ± 0.021
26 DC 1.79 ± 0.029 A 1.94 ± 0.051
9 LC 0.74 ± 0.002 D 0.75 ± 0.003
17 DC 0.79 ± 0.003 D 0.83 ± 0.009
1 PC 1.28 ± 0.013 A 0.86 ± 0.001
2 PO 2.43 ± 0.079 A 0.55 ± 0.022
27 DC 0.56 ± 0.006 D 1.63 ± 0.016
24 DC 0.68 ± 0.009 D 1.87 ± 0.004
8 DC 1.33 ± 0.003 A 0.55 ± 0.001
11 LC 0.87 ± 0.021 D 1.52 ± 0.022
20 DC 1.15 ± 0.023 A 0.85 ± 0.027
23 NI 2.88 ± 0.015 A 0.78 ± 0.004
7 NI 1.45 ± 0.003 A 1.84 ± 0.003
15 DC 3.06 ± 0.004 A 1.98 ± 0.003
19 DC 4.68 ± 0.085 A 2.45 ± 0.049
29 DC 1.25 ± 0.031 A 1.07 ± 0.050
32 DC/LC 1.44 ± 0.051 A 1.26 ± 0.041
30 DC 0.70 ± 0.005 D 0.65 ± 0.004
31 NI 0.28 ± 0.001 D 0.33 ± 0.002
21 TC 1.13 ± 0.001 A 0.49 ± 0.001
Abbreviations: Alt – alteration; D – deletion; A – ampliﬁcation; DC – invasive ductal ca
carcinoma; PO – poorly differentiated carcinoma; NI – no information.
Values in bold indicate alterations are not consistent within groups ACHE–EPHB4 and BCep realplex (Eppendorf) and Realplex 1.5 Eppendorf Software were
used to determine sample concentrations (ng/ll).2.3. Statistical analysis
For each sample, a ratio (Q) was calculated between the mean
amounts of target and reference genes in the tumor and in periph-
eral blood [22,10].
To determine the type of change (ampliﬁcation or deletion) of
the genes for each sample it was calculated an average of the Q
values and an average of the standard deviation (SD) values using
two reference genes with consistent results. If mean Q ± mean
S.D. > 1, the samples are ampliﬁed. If mean Q ± mean S.D. < 1,
the samples are deleted (using a 95% conﬁdence interval). Spear-
man correlation and logistic regression test between the results
obtained and the clinical histopathological data were accom-
plished using Bioestat 5.0.3. Results and discussion
All patient samples showed gene ampliﬁcations or deletions
(Table 1). It was observed a tendency for ampliﬁcation of the ACHE
(62.5% vs. 37.5%; p > 0.1) and the EPHB4 (53.13% vs. 46.88%; p > 0.5)
genes and for deletions of the BCHE (56.25% vs. 43.75%; p > 0.5) and
the MME (56.25% vs. 43.75%; p > 0.5) genes (Fig. 1). Positive corre-
lations were found between alterations of the ACHE and the EPHB4
genes (rs = 0.5948; p = 0.0004) and between the BCHE and theMME
genes (rs = 0.3581; p = 0.0478).
In this study, the investigation of changes in the copy number of
the ACHE and BCHE gene regions showed results consistent with32 patients with sporadic breast cancer, grouped according to the alterations obtained.
ean) Alt BCHE Q(mean) ± S.D.(mean) Alt MME Q(mean) ± S.D.(mean) Atl
A 1.13 ± 0.002 A 1.38 ± 0.002 A
A 1.23 ± 0.003 A 1.88 ± 0.012 A
A 1.27 ± 0.001 A 1.15 ± 0.001 A
A 1.23 ± 0.019 A 1.06 ± 0.017 A
D 0.75 ± 0.001 D 0.74 ± 0.001 D
D 0.92 ± 0.001 D 0.77 ± 0.002 D
D 0.67 ± 0.001 D 0.47 ± 0.001 D
D 0.56 ± 0.002 D 0.45 ± 0.002 D
D 0.68 ± 0.022 D 0.57 ± 0.012 D
A 0.80 ± 0.009 D 0.84 ± 0.010 D
A 0.82 ± 0.001 D 0.90 ± 0.002 D
A 0.54 ± 0.001 D 0.80 ± 0.005 D
A 0.59 ± 0.013 D 0.68 ± 0.016 D
A 0.59 ± 0.010 D 0.72 ± 0.012 D
D 1.68 ± 0.005 A 1.65 ± 0.002 A
D 1.30 ± 0.006 A 1.15 ± 0.006 A
D 1.34 ± 0.002 A 1.38 ± 0.002 A
D 1.50 ± 0.697 A 2.39 ± 0.073 A
A 2.55 ± 0.025 A 2.03 ± 0.020 A
A 1.86 ± 0.004 A 1.44 ± 0.002 A
D 0.59 ± 0.003 D 0.62 ± 0.002 D
A 0.56 ± 0.004 D 0.80 ± 0.012 D
D 0.86 ± 0.027 D 0.76 ± 0.015 D
D 0.78 ± 0.005 D 0.78 ± 0.004 D
A 0.60 ± 0.001 D 1.67 ± 0.002 A
A 0.55 ± 0.001 D 1.40 ± 0.009 A
A 1.67 ± 0.033 A 0.61 ± 0.012 D
A 1.06 ± 0.026 A 0.83 ± 0.021 D
A 7.60 ± 0.261 A 0.67 ± 0.030 D
D 0.60 ± 0.003 D 1.14 ± 0.008 A
D 4.08 ± 0.019 A 0.51 ± 0.003 D
D 0.68 ± 0.001 D 1.63 ± 0.001 A




































Fig. 1. Alterations presented by genes ACHE, EPHB4, BCHE and MME. It was
observed a trend to greater ampliﬁcation (amp) in pair ACHE–EPHB4 and deletion
(del) in the BCHE–MME pair. The order of alterations (del/del/; amp/del; del/amp;
amp/amp) follow the same order of the genes (ACHE/EPHB4; BCHE/MME).
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[23], analyzing structural alterations in phyllodes tumor, noted a
frequent 7q gain and 3q loss, suggesting some pathogenic similar-
ity with breast carcinoma. It is also accordant with the altered
behavior of cholinesterases activity in breast cancer: one study
showed a statistically signiﬁcant increase (twice) of AChE and de-
crease of 65% of BChE activity [24].
Ampliﬁcation of chromosome 7 is among the most frequent
cytogenetic abnormalities found in breast carcinoma. Forozan et
al. [25] studying 11 breast cancer cell lines noted that two third
of the sites of ampliﬁcations was performed in loci not associated
with already established oncogenes, such as 7q21-q22, reinforcing
the hypothesis that this region may harbor candidate oncogenes
[26,27]. Next to this region is located a proto oncogene, MET
(7q31), that encodes a growth factor receptor and is associated
with protein kinases of other oncogenes [28]. Its signaling can pro-
mote unregulated cell proliferation in normal mammary gland, a
necessary event in maintaining the functional and phenotypic
properties of tumors [29].
Based on the fact that the high expression of EphB4, resulting
from gene ampliﬁcation, causes an increase in angiogenic potential
of breast cells and facilitates tumor invasion [16,30,31], regression
tests were performed to verify if EPHB4 gene alterations are inde-
pendent risk factors for the process of metastasis, but none of the
results were statistically signiﬁcant (p > 0.05).
Deletions in the long arm of chromosome 3 appear to be late
events in the breast cancer progression because allelic losses or
imbalances affecting these areas were rarely observed in in situ
ductal carcinoma, and were more frequent in invasive stage and
lymph node metastases [32,33]. The expression of neprylisin in
invasive ductal carcinoma is closely linked to an aggressive biolog-
ical behavior, thus facilitating the invasion and metastasis of mam-
mary carcinoma [34].
Such studies corroborate the trend to higher deletions of MME
gene, as obtained in this work, however the logistic regression testwith lymph node metastasis (as independent variable) and altera-
tions of MME gene were not statistically signiﬁcant (p > 0.05).
Despite the many indications of the involvement of BChE and
neprylisin in oncogenesis, the structural changes may have oc-
curred accidentally by the proximity of these genes to known proto
oncogenes.
One of the most studied is the PIK3CA, that encodes a subunit of
PI3K (phosphatidylinositol 3-kinase) an enzyme that participates
in the regulation of cell proliferation, adhesion and motility, mainly
by mediating the signaling of the epidermal growth factor. Changes
in the components of the PI3K pathway are common in breast can-
cer [35,36].
It is possible to infer that the ampliﬁcations and deletions re-
vealed here cover a much larger area than just the genes ACHE
and BCHE, and even though the cholinesterases, as well as the
receptor EphB4 and neprylisin exert some inﬂuence on tumorigen-
esis, we cannot say that there is a direct causal relationship of these
proteins in tumor development. The copy number variation of these
genes can be seen as a consequence of the neoplastic process, which
somehow could be advantageous to disease progression.Conﬂict of interest
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